Secondary Treatment for Men with Localized Prostate Cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform

Katharina Beyer; Vera  Straten; Sebastiaan Remmers; Steven MacLennan; Giorgio Gandaglia; Peter-Paul M.  Willemse; Ronald  Herrera; Muhammad Imran Omar; Beth  Russell; Johannes Huber; Markus  Kreuz; Alex Asiimwe; Tom  Abbott; Alberto Briganti; Mieke  Vanhemelrijck; Monique J Roobol; Sara MacLennan; null The PRIAS Consortium; null The ERSPC Rotterdam Study Group; null The PIONEER Consortium

doi:10.3390/jpm12050751

Secondary Treatment for Men with Localized Prostate Cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform

Katharina Beyer^* (Corresponding Author), Vera Straten, Sebastiaan Remmers, Steven MacLennan, Giorgio Gandaglia, Peter-Paul M. Willemse, Ronald Herrera, Muhammad Imran Omar, Beth Russell, Johannes Huber, Markus Kreuz, Alex Asiimwe, Tom Abbott, Alberto Briganti, Mieke Vanhemelrijck, Monique J Roobol, Sara MacLennan, The PRIAS Consortium, The ERSPC Rotterdam Study Group, The PIONEER Consortium

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change.

METHODS: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT).

RESULTS: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively.

CONCLUSION: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).

Original language	English
Article number	751
Number of pages	8
Journal	Journal of Personalized Medicine
Volume	12
Issue number	5
Early online date	5 May 2022
DOIs	https://doi.org/10.3390/jpm12050751
Publication status	Published - 5 May 2022
Event	EAU21 Virtual Congress - Virtual Duration: 8 Jul 2021 → 12 Aug 2021 https://eaucongress.uroweb.org

Keywords

prostate cancer
active surveillance
treatment choice
patient decision-making
oncology
treatment selection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jpm12050751Licence: CC BY

Beyer_etal_JPM_Secondary_Treatment_For_VOR
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license https://creativecommons.org/licenses/by/4.0/, any part of the article may be reused without permission provided that the original article is clearly cited.
Final published version, 416 KBLicence: CC BY

Cite this

Beyer, K., Straten, V., Remmers, S., MacLennan, S., Gandaglia, G., Willemse, P-P. M., Herrera, R., Omar, M. I., Russell, B., Huber, J., Kreuz, M., Asiimwe, A., Abbott, T., Briganti, A., Vanhemelrijck, M., Roobol, M. J., MacLennan, S., The PRIAS Consortium, The ERSPC Rotterdam Study Group, & The PIONEER Consortium (2022). Secondary Treatment for Men with Localized Prostate Cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform. Journal of Personalized Medicine, 12(5), [751]. https://doi.org/10.3390/jpm12050751

Secondary Treatment for Men with Localized Prostate Cancer : a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform. / Beyer, Katharina (Corresponding Author); Straten, Vera ; Remmers, Sebastiaan et al.

In: Journal of Personalized Medicine, Vol. 12, No. 5, 751, 05.05.2022.

Research output: Contribution to journal › Article › peer-review

Beyer, K, Straten, V, Remmers, S, MacLennan, S, Gandaglia, G, Willemse, P-PM, Herrera, R, Omar, MI, Russell, B, Huber, J, Kreuz, M, Asiimwe, A, Abbott, T, Briganti, A, Vanhemelrijck, M, Roobol, MJ, MacLennan, S, The PRIAS Consortium, The ERSPC Rotterdam Study Group & The PIONEER Consortium 2022, 'Secondary Treatment for Men with Localized Prostate Cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform', Journal of Personalized Medicine, vol. 12, no. 5, 751. https://doi.org/10.3390/jpm12050751

@article{2c12f38b3c434a22b49c8728aa533ed6,

title = "Secondary Treatment for Men with Localized Prostate Cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform",

abstract = "INTRODUCTION: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change.METHODS: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT).RESULTS: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively.CONCLUSION: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).",

keywords = "prostate cancer, active surveillance, treatment choice, patient decision-making, oncology, treatment selection",

author = "Katharina Beyer and Vera Straten and Sebastiaan Remmers and Steven MacLennan and Giorgio Gandaglia and Willemse, {Peter-Paul M.} and Ronald Herrera and Omar, {Muhammad Imran} and Beth Russell and Johannes Huber and Markus Kreuz and Alex Asiimwe and Tom Abbott and Alberto Briganti and Mieke Vanhemelrijck and Roobol, {Monique J} and Sara MacLennan and {The PRIAS Consortium} and {The ERSPC Rotterdam Study Group} and {The PIONEER Consortium}",

note = "Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation program and EFPIA. The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.; EAU21 Virtual Congress ; Conference date: 08-07-2021 Through 12-08-2021",

year = "2022",

month = may,

day = "5",

doi = "10.3390/jpm12050751",

language = "English",

volume = "12",

journal = "Journal of Personalized Medicine",

issn = "2075-4426",

publisher = "MDPI",

number = "5",

url = "https://eaucongress.uroweb.org",

}

TY - JOUR

T1 - Secondary Treatment for Men with Localized Prostate Cancer

T2 - EAU21 Virtual Congress

AU - Beyer, Katharina

AU - Straten, Vera

AU - Remmers, Sebastiaan

AU - MacLennan, Steven

AU - Gandaglia, Giorgio

AU - Willemse, Peter-Paul M.

AU - Herrera, Ronald

AU - Omar, Muhammad Imran

AU - Russell, Beth

AU - Huber, Johannes

AU - Kreuz, Markus

AU - Asiimwe, Alex

AU - Abbott, Tom

AU - Briganti, Alberto

AU - Vanhemelrijck, Mieke

AU - Roobol, Monique J

AU - MacLennan, Sara

AU - The PRIAS Consortium, null

AU - The ERSPC Rotterdam Study Group, null

AU - The PIONEER Consortium, null

N1 - Funding PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation program and EFPIA. The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

PY - 2022/5/5

Y1 - 2022/5/5

N2 - INTRODUCTION: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change.METHODS: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT).RESULTS: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively.CONCLUSION: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).

AB - INTRODUCTION: Treatment choice for localized prostate cancer is complicated, as each treatment option comes with various pros and cons. It is well established that active surveillance (AS), may be ended with a change to curative treatment at the time of disease progression, but it is less clear whether secondary treatment after initial curative treatment is required. As part of the PIONEER project, we quantified the probabilities of treatment change.METHODS: A cohort study based on PRIAS and ERSPC-Rotterdam data was conducted. Patients were followed up for 10 years or until the 31st of December 2017. The primary outcome was the incidence of treatment change following initial treatment (i.e., a change to curative treatment following AS or secondary treatment after initial RP/RT).RESULTS: Over a period of 1 to 5 years after initial treatment, the cumulative incidence of treatment change ranged from 3.8% to 42.8% for AS, from 7.6% to 12.1% for radical prostatectomy (RP) and from no change to 5.3% for radiation therapy (RT). While the possibility of treatment change in AS is known, the numbers within a five-year period were substantial. For RP and RT, the rate of change to secondary treatment was lower, but still non-neglectable, with 5 (10)-year incidences up to 12% (20%) and 5% (16%), respectively.CONCLUSION: This is one of the first studies comparing the incidence of guideline-recommended treatment changes in men receiving different primary treatments (i.e., AS, RT, or RP) for localized prostate cancer (PCa).

KW - prostate cancer

KW - active surveillance

KW - treatment choice

KW - patient decision-making

KW - oncology

KW - treatment selection

U2 - 10.3390/jpm12050751

DO - 10.3390/jpm12050751

M3 - Article

C2 - 35629173

VL - 12

JO - Journal of Personalized Medicine

JF - Journal of Personalized Medicine

SN - 2075-4426

IS - 5

M1 - 751

Y2 - 8 July 2021 through 12 August 2021

ER -

Secondary Treatment for Men with Localized Prostate Cancer: a pooled analysis of PRIAS and ERSPC-Rotterdam data within the PIONEER data platform

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this